Company Alphamab Oncology

Equities

9966

KYG0330A1013

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Alphamab Oncology

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 03:24:51 2024-06-07 am EDT			5-day change	1st Jan Change
2.86 ^HKD	-0.69%		+12.60%	-56.93%

Jun. 05	ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment	MT
Jun. 05	Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates	MT

Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.

Number of employees: 435

HKD in Million	2022	Weight	2023	Weight	Delta
Biologics of Oncology 100.0 %	194	100.0 %	242	100.0 %	+24.60%

HKD in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	194	100.0 %	242	100.0 %	+24.60%

Managers	Title	Age	Since
Ting Xu CEO	Chief Executive Officer	51	08-10-31
Jing Han CMP	Compliance Officer	51	21-11-01
Jinbo Wang CTO	Chief Tech/Sci/R&D Officer	50	18-03-18
Liang Kong CTO	Chief Tech/Sci/R&D Officer	44	18-05-31
Lu Amy Sun CTO	Chief Tech/Sci/R&D Officer	67	19-05-31
Yang Liu COO	Chief Operating Officer	52	18-09-30
Jin Nan Wang IRC	Investor Relations Contact	42	-
Shaowei Yang PRN	Corporate Officer/Principal	48	17-06-12
Mike Liu PRN	Corporate Officer/Principal	58	18-04-30
Lok Yee Chan SEC	Corporate Secretary	35	-

Members of the board	Title	Age	Since
Cheng Wei BRD	Director/Board Member	56	19-11-23
Ting Xu CEO	Chief Executive Officer	51	08-10-31
Yang Liu COO	Chief Operating Officer	52	18-09-30
Dong Wu BRD	Director/Board Member	54	19-11-23
Zijian Guo BRD	Director/Board Member	63	21-08-26

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	964,923,807	474,870,857 ( 49.21 %)	0	49.21 %

Name	Equities	%	Valuation
Ting Xu 33.02 %	318,552,950	33.02 %	193 M $
Chuan Xiao Xue 8.887 %	85,750,000	8.887 %	52 M $
Xi Tian Zhang 8.887 %	85,750,000	8.887 %	52 M $
Advantech Advisors (HK) Limited 4.861 %	46,897,190	4.861 %	28 M $
Zhong Ou Asset Management Co., Ltd 1.660 %	16,019,563	1.660 %	10 M $
GF Fund Management Co., Ltd. 1.238 %	11,946,000	1.238 %	7 M $
First Seafront Fund Management Co., Ltd. 0.8828 %	8,518,000	0.8828 %	5 M $
Bosera Asset Management Co., Ltd. 0.3433 %	3,312,000	0.3433 %	2 M $
China Asset Management Co., Ltd. 0.2271 %	2,191,000	0.2271 %	1 M $
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt) 0.1220 %	1,177,000	0.1220 %	714 816 $

Alphamab Oncology

175 Fangzhou Road Suzhou Industrial Park

215127, Suzhou

http://www.alphamabonc.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.671 CNY

Average target price

3.295 CNY

Spread / Average Target

+23.34%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALPHAMAB ONCOLOGY	-56.93%	356M
MODERNA, INC.	+55.55%	59.28B
LONZA GROUP AG	+42.83%	40.94B
IQVIA HOLDINGS INC.	-4.71%	40.17B
CELLTRION, INC.	-5.56%	28.69B
ICON PUBLIC LIMITED COMPANY	+13.76%	26.63B
ALNYLAM PHARMACEUTICALS, INC.	-22.00%	18.89B
MEDPACE HOLDINGS, INC.	+31.50%	12.46B
BIO-TECHNE CORPORATION	+2.16%	12.42B
UNITED THERAPEUTICS CORPORATION	+25.70%	12.26B

Other Biotechnology & Medical Research